Beth Weinberg - Cara Therapeutics VP QA

All Insiders . Germany . 
Stock . Cara Therapeutics . Stakeholders . Insider . Beth Weinberg
69C Stock  EUR 4.84  0.00  0.00%   

Insider

Beth Weinberg is VP QA of Cara Therapeutics
Phone203 406 3700
Webhttps://www.caratherapeutics.com

Cara Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4516) %, meaning that it generated substantial loss on money invested by shareholders. Cara Therapeutics' management efficiency ratios could be used to measure how well Cara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Cara Therapeutics has accumulated 4.99 M in total debt with debt to equity ratio (D/E) of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cara Therapeutics has a current ratio of 3.33, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cara Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cara Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cara Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cara to invest in growth at high rates of return. When we think about Cara Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Eivind KallevikNorsk Hydro ASA
56
JeanJacques HenchozTalanx AG
59
William IIReliance Steel Aluminum
55
Sven PetterssonSIVERS SEMICONDUCTORS AB
60
Karla LewisReliance Steel Aluminum
57
Arthur AjemyanReliance Steel Aluminum
47
Mike TaylorIdentiv
N/A
Michael ShanleyReliance Steel Aluminum
65
Stephen KochReliance Steel Aluminum
56
Amir KhoshniyatiIdentiv
N/A
Pal KildemoNorsk Hydro ASA
39
Steven HumphreysIdentiv
62
Jeffrey DurhamReliance Steel Aluminum
60
Erik FallstromSIVERS SEMICONDUCTORS AB
56
Torsten LeueTalanx AG
57
Hilde NordhNorsk Hydro ASA
54
Paul WartonNorsk Hydro ASA
62
James DevensSuperior Plus Corp
N/A
FCA FCASuperior Plus Corp
68
Ingrid EngstromSIVERS SEMICONDUCTORS AB
59
Robert SmithNMI Holdings
53
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people. Cara Therapeutics (69C) is traded on Frankfurt Exchange in Germany and employs 84 people.

Management Performance

Return On Equity-0.45
Return On Asset-0.26

Cara Therapeutics Leadership Team

Elected by the shareholders, the Cara Therapeutics' board of directors comprises two types of representatives: Cara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutics' management team and ensure that shareholders' interests are well served. Cara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joana Goncalves, Chief Medical Officer
Christopher Posner, Director
Beth Weinberg, VP QA
Eric Vandal, VP Commercial
Frdrique Menzaghi, Chief RD
Iris Francesconi, Chief Relations
Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary
Dr DSc, CoFounder Advisor
Ryan Maynard, Chief Officer

Cara Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.45
Return On Asset-0.26
Profit Margin(2.25) %
Operating Margin(2.28) %
Current Valuation450.58 M
Shares Outstanding53.73 M
Shares Owned By Insiders16.10 %
Shares Owned By Institutions65.69 %
Price To Book3.33 X
Price To Sales14.36 X

Currently Active Assets on Macroaxis

BTCBitcoin
TRXTRON
BNBBinance Coin
ADACardano
XRPXRP

Other Information on Investing in Cara Stock

Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY